Cargando…

Non-adherence to disease-modifying antirheumatic drugs is associated with higher disease activity in early arthritis patients in the first year of the disease

INTRODUCTION: Non-adherence to disease-modifying antirheumatic drugs (DMARDs) hampers the targets of rheumatoid arthritis (RA) treatment, obtaining low disease activity and decreasing radiological progression. This study investigates if, and to what extent, non-adherence to treatment would lead to a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pasma, Annelieke, Schenk, Charlotte V., Timman, Reinier, Busschbach, Jan J. V., van den Bemt, Bart J.F., Molenaar, Esmeralda, van der Laan, Willemijn H., Schrauwen, Saskia, van’t Spijker, Adriaan, Hazes, Johanna M. W.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4599322/ https://www.ncbi.nlm.nih.gov/pubmed/26449852 http://dx.doi.org/10.1186/s13075-015-0801-4

Ejemplares similares

Does non-adherence to DMARDs influence hospital-related healthcare costs for early arthritis in the first year of treatment?
por: Pasma, Annelieke, et al.
Publicado: (2017)

Focus group interviews reveal reasons for differences in the perception of disease activity in rheumatoid arthritis
por: Walter, Margot J. M., et al.
Publicado: (2016)

How to study determinants related to medication adherence in newly diagnosed polyarthritis patients for the development of a prediction instrument
por: Pasma, Annelieke, et al.
Publicado: (2014)

Preferences of patients with rheumatoid arthritis regarding disease-modifying antirheumatic drugs: a discrete choice experiment
por: van Heuckelum, Milou, et al.
Publicado: (2019)

Effective Group Training for Patients with Unexplained Physical Symptoms: A Randomized Controlled Trial with a Non-Randomized One-Year Follow-Up
por: Zonneveld, Lyonne N. L., et al.
Publicado: (2012)

Correction: Effective Group Training for Patients with Unexplained Physical Symptoms: A Randomized Controlled Trial with a Non-Randomized One-Year Follow-Up
por: Zonneveld, Lyonne N. L., et al.
Publicado: (2013)

Predicting the outcome of a cognitive-behavioral group training for patients with unexplained physical symptoms: a one-year follow-up study
por: Zonneveld, Lyonne NL, et al.
Publicado: (2012)

Barriers and facilitators to disease-modifying antirheumatic drug use in patients with inflammatory rheumatic diseases: a qualitative theory-based study
por: Voshaar, Marieke, et al.
Publicado: (2016)

A discrete choice experiment on preferences of patients with rheumatoid arthritis regarding disease-modifying antirheumatic drugs: the identification, refinement, and selection of attributes and levels
por: Mathijssen, Elke GE, et al.
Publicado: (2018)

A Serious Puzzle Game to Enhance Adherence to Antirheumatic Drugs in Patients With Rheumatoid Arthritis: Systematic Development Using Intervention Mapping
por: Pouls, Bart PH, et al.
Publicado: (2022)

The impact of biologics on health-related quality of life in patients with inflammatory bowel disease
por: Vogelaar, Lauran, et al.
Publicado: (2009)

Group cognitive behavioural therapy and weight regain after diet in type 2 diabetes: results from the randomised controlled POWER trial
por: Berk, Kirsten A., et al.
Publicado: (2018)

Implicit and explicit attitudes towards disease-modifying antirheumatic drugs as possible target for improving medication adherence
por: van Heuckelum, M., et al.
Publicado: (2019)

Logical inconsistencies in time trade-off valuation of EQ-5D-5L health states: Whose fault is it?
por: Yang, Zhihao, et al.
Publicado: (2017)

The Prevention Of WEight Regain in diabetes type 2 (POWER) study: the effectiveness of adding a combined psychological intervention to a very low calorie diet, design and pilot data of a randomized controlled trial
por: Berk, Kirsten AC, et al.
Publicado: (2012)

Antirheumatic drugs for cardiovascular disease prevention: the case for colchicine
por: Lems, Willem, et al.
Publicado: (2021)

Impact of the Coronavirus Disease Pandemic on Health-Related Quality of Life of Patients with Inflammatory Bowel Disease
por: Paulides, Emma, et al.
Publicado: (2021)

Six and eight weeks injection frequencies of bevacizumab are non-inferior to the current four weeks injection frequency for quality of life in neovascular age-related macular degeneration: a randomized controlled trial
por: Visser, Martijn S., et al.
Publicado: (2020)

Molecular mechanisms of resistance to disease modifying antirheumatic drugs (DMARDs)
por: Jansen, G, et al.
Publicado: (2002)

The development of the DISCO-RC for measuring children’s discomfort during research procedures
por: Staphorst, Mira S., et al.
Publicado: (2017)

SF-6D utility values for the better- and worse-seeing eye for health states based on the Snellen equivalent in patients with age-related macular degeneration
por: Visser, Martijn S., et al.
Publicado: (2017)

Systematic review of disease-modifying antirheumatic drugs for juvenile idiopathic arthritis
por: Kemper, Alex R, et al.
Publicado: (2012)

A very short version of the Visual Function Questionnaire (VFQ‐3oo7) for use as a routinely applied Patient‐Reported Outcome Measure
por: Visser, Martijn S., et al.
Publicado: (2020)

Digital Outcome Measurement to Improve Care for Patients With Immune-Mediated Inflammatory Diseases: Protocol for the IMID Registry
por: Looijen, Agnes E M, et al.
Publicado: (2023)

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update
por: Smolen, Josef S, et al.
Publicado: (2014)

Intralesional cryotherapy versus excision and corticosteroids or brachytherapy for keloid treatment: study protocol for a randomised controlled trial
por: Bijlard, Eveline, et al.
Publicado: (2013)

Predictors of Diet-Induced Weight Loss in Overweight Adults with Type 2 Diabetes
por: Berk, Kirsten A., et al.
Publicado: (2016)

The effectiveness of a training for patients with unexplained physical symptoms: protocol of a cognitive behavioral group training and randomized controlled trial
por: Zonneveld, Lyonne NL, et al.
Publicado: (2009)

Long-term effects of a three-component lifestyle intervention on emotional well-being in women with Polycystic Ovary Syndrome (PCOS): A secondary analysis of a randomized controlled trial
por: Jiskoot, Geranne, et al.
Publicado: (2020)

Weight Reduction Through a Cognitive Behavioral Therapy Lifestyle Intervention in PCOS: The Primary Outcome of a Randomized Controlled Trial
por: Jiskoot, Geranne, et al.
Publicado: (2020)

Changes in eating behavior through lifestyle treatment in women with polycystic ovary syndrome (PCOS): a randomized controlled trial
por: Jiskoot, Geranne, et al.
Publicado: (2022)

Lifestyle treatment in women with polycystic ovary syndrome: predictors of weight loss and dropout
por: Jiskoot, Geranne, et al.
Publicado: (2022)

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs
por: Smolen, Josef S, et al.
Publicado: (2010)

Safety and Efficacy of Baricitinib in Patients Receiving Conventional Synthetic Disease-Modifying Antirheumatic Drugs or Corticosteroids
por: van Vollenhoven, Ronald, et al.
Publicado: (2018)

Adaptation and validation of the Dutch version of the nasal obstruction symptom evaluation (NOSE) scale
por: van Zijl, Floris V. W. J., et al.
Publicado: (2017)

Behavioural, psychiatric and psychosocial factors associated with aggressive behaviour in adults with intellectual disabilities: A systematic review and narrative analysis
por: van den Akker, Natalie, et al.
Publicado: (2020)

Patients with unexplained physical symptoms have poorer quality of life and higher costs than other patient groups: a cross-sectional study on burden
por: Zonneveld, Lyonne NL, et al.
Publicado: (2013)

Are biologics more effective than classical disease-modifying antirheumatic drugs?
por: Nurmohamed, Michael T, et al.
Publicado: (2008)

Gold Finger: Metal Jewellery as a Disease Modifying Antirheumatic Therapy!
por: Hlaing, T., et al.
Publicado: (2009)

Biologic and oral disease-modifying antirheumatic drug monotherapy in rheumatoid arthritis
por: Emery, Paul, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_ejit81tvl0p715cln61todu631